# Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes

> **NCT05975528** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 92 (estimated)

## Conditions studied

- Diabetes Mellitus
- Cellular Senescence
- Sodium-Glucose Transporter 2 Inhibitors

## Interventions

- **DRUG:** SGLT2 inhibitor
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT05975528
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975528, "Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05975528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*